Press Release | Sun Dec 9, 2012 4:30pm EST

Elotuzumab Progression-Free Survival Data from Phase 2 Study of Patients with Previously-Treated Multiple Myeloma Presented at 54th American Society of Hematology (ASH) Annual Meeting

* Reuters is not responsible for the content in this press release.